Adelaide A. Hebert, MD

Articles by Adelaide A. Hebert, MD

Implications of Boxed Warnings of Topical JAK inhibitors

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

March 1st 2023

Expert dermatologists address the clinical implications of boxed warnings of topical treatments in AD.

Time to Response in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

February 22nd 2023

Matthew Zirwas, MD, and Omar Noor, MD, comment on their own experience of time to response with topical and systemic treatments of AD.

Durability of Response to Treatment in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

February 22nd 2023

Peter A. Lio, MD, discusses the durability of topical treatments in AD, including steroids, calcineurin inhibitors, and JAK inhibitors.

Efficacy Data for Topical Treatment of AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

February 15th 2023

Experts discuss long-term efficacy data for topical medications for the treatment of AD.

Patient With Limited Disease Activity in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

February 15th 2023

Matthew Zirwas, MD, and Omar Noor, MD, review a patient scenario where AD disease activity is limited but in difficult to treat locations.

AD Treatment Options for Patients Moving Away from Long-Term Steroids

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

February 8th 2023

Peter A. Lio, MD, shares his approach to presenting treatment alternatives to patients who want to stop using long-term steroids for treatment of AD.

Challenges Faced by Non-Dermatologists When Using Steroids

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

February 8th 2023

Adelaide A. Hebert, MD, comments on the need for nondermatologist education on the basics of skin disease care.

Durability of Topical Steroid Use in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

February 1st 2023

Expert dermatologists discuss the durability of long-term use of topical steroids for treatment of atopic dermatitis.

Patient on Long-Term Steroidal Use in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

February 1st 2023

Adelaide A. Hebert, MD, reviews the use of long-term steroids for treatment of atopic dermatitis.

Factors Guiding Treatment Selection in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

January 26th 2023

Experts in dermatology discuss which disease characteristics play the biggest role in influencing treatment choice or change of treatment from the perspective of a patient with atopic dermatitis.

Treatment Options and Targets in Atopic Dermatitis (AD)

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

January 25th 2023

A panel of expert dermatologists comments on newly approved and traditional treatment options, addressing how they target inflammation and the pathophysiology of atopic dermatitis (AD).